These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2647015)

  • 1. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.
    Barlogie B; Smallwood L; Smith T; Alexanian R
    Ann Intern Med; 1989 Apr; 110(7):521-5. PubMed ID: 2647015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma.
    Suguro M; Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
    Am J Hematol; 2000 Oct; 65(2):132-5. PubMed ID: 10996830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
    Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
    Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features.
    Niesvizky R; Siegel D; Glassman J; Straus D; Fine J; Lyons L; Michaeli J
    Leuk Lymphoma; 2002 Mar; 43(3):607-12. PubMed ID: 12002766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
    Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
    J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma.
    Simonsson B; Brenning G; Källander C; Ahre A
    Eur J Clin Invest; 1987 Aug; 17(4):336-9. PubMed ID: 3117570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
    Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
    Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
    Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
    J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology and therapy of multiple myeloma.
    Barlogie B; Alexanian R
    Acta Haematol; 1987; 78 Suppl 1():171-4. PubMed ID: 3124442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors with high-dose melphalan for refractory multiple myeloma.
    Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
    Blood; 1988 Dec; 72(6):2015-9. PubMed ID: 3196876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of primary resistant and relapsed multiple myeloma.
    Barlogie B; Alexanian R
    Onkologie; 1986 Aug; 9(4):210-4. PubMed ID: 3531948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate dehydrogenase and its isoenzymes in serum from patients with multiple myeloma.
    Copur S; Kus S; Kars A; Renda N; Tekuzman G; Firat D
    Clin Chem; 1989 Sep; 35(9):1968-70. PubMed ID: 2776328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV; Andreeva NE; Izgorodin AS
    Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
    Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
    Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.
    Bang SM; Cho EK; Suh C; Yoon SS; Seong CM; Cho KS; Kang YG; Park S; Ahn MJ; Park YS; Oh D; Kim HC; Jung CW; Kim S; Lee JH
    J Korean Med Sci; 2003 Oct; 18(5):673-8. PubMed ID: 14555819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.